NCT05600738Recruiting
Network Effects of Therapeutic Deep Brain Stimulation
Source: ClinicalTrials.gov · Last updated 31 Oct 2022 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The purpose of this study is to map the acute, short-term cortical evoked responses to thalamic electrical stimulation in persons with intractable epilepsy
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- First submitted
- 25 Oct 2022
- Start date
- 26 Aug 2022
- Primary completion date
- 31 Jul 2027
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Diseases
- Epilepsy
- NCT number
- NCT05600738
What you commit to
- Study type: Interventional
- Planned participants: 25
- From 26 Aug 2022 to the primary completion date, 31 Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- pregnant women
- active psychosis, major depression, or suicidal ideation in the preceding year
- Intelligence quotient (IQ) less than 70 as measured by clinical neuropsychological evaluation
- Do not agree to share their medical records for research purposes
Who the study is looking for
- diagnosis of Epilepsy
- undergoing neuromodulation therapy with clinically implanted neuromodulation devices (DBS, RNS)
- followed in the outpatient epilepsy clinic
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The University of Texas Health Science Center at Houston Coordinator of this site? Confirm its status | Houston | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.